logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASH 2018 — Frontline ibrutinib tops chemoimmunotherapy for CLL in older patients

Phase 3 data show significantly lower rate of disease progression vs bendamustine plus rituximab.